Comparing Revenue Performance: United Therapeutics Corporation or Perrigo Company plc?

Pharma Giants' Revenue Battle: United Therapeutics vs. Perrigo

__timestampPerrigo Company plcUnited Therapeutics Corporation
Wednesday, January 1, 201440608000001288519000
Thursday, January 1, 201546039000001465761000
Friday, January 1, 201652806000001598800000
Sunday, January 1, 201749462000001725300000
Monday, January 1, 201847317000001627800000
Tuesday, January 1, 201948374000001448800000
Wednesday, January 1, 202050633000001483300000
Friday, January 1, 202141387000001685500000
Saturday, January 1, 202244516000001936300000
Sunday, January 1, 202346556000002327500000
Loading chart...

Unleashing insights

Revenue Showdown: United Therapeutics vs. Perrigo

In the competitive landscape of the pharmaceutical industry, revenue performance is a key indicator of success. From 2014 to 2023, United Therapeutics Corporation and Perrigo Company plc have shown distinct revenue trajectories. Perrigo, with a consistent revenue stream, peaked in 2016 with a 30% increase from 2014, before stabilizing around $4.5 billion annually. In contrast, United Therapeutics demonstrated a robust growth pattern, with revenue surging by approximately 80% over the same period, reaching its zenith in 2023. This growth reflects United Therapeutics' strategic advancements and market adaptability. While Perrigo maintains a larger revenue base, United Therapeutics' rapid growth highlights its potential to challenge industry norms. As the pharmaceutical sector evolves, these companies' revenue trends offer insights into their strategic directions and market positions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025